104 179

Cited 0 times in

Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis

Authors
 Yoon Jee Lee  ;  Jae Hee Cheon  ;  Jae Hyun Kim  ;  SunHo Yoo  ;  Hyun Jung Lee  ;  Soo Jung Park  ;  Sung Pil Hong  ;  Tae Il Kim  ;  Won Ho Kim 
Citation
 YONSEI MEDICAL JOURNAL, Vol.58(1) : 144-149, 2017 
Journal Title
 YONSEI MEDICAL JOURNAL 
ISSN
 0513-5796 
Issue Date
2017
MeSH
Administration, Oral ; Anti-Inflammatory Agents/administration & dosage* ; Anti-Inflammatory Agents/adverse effects ; Beclomethasone/administration & dosage* ; Beclomethasone/adverse effects ; Colitis, Ulcerative/drug therapy ; Drug-Related Side Effects and Adverse Reactions ; Female ; Humans ; Male ; Medical Records ; Remission Induction ; Republic of Korea ; Retrospective Studies ; Safety ; Treatment Outcome ; Young Adult
Keywords
Beclomethasone dipropionate ; clinical remission ; clinical response ; ulcerative colitis
Abstract
PURPOSE: Our aim was to evaluate the efficacy and safety of oral beclomethasone dipropionate (BDP) in Korean patients with ulcerative colitis (UC). MATERIALS AND METHODS: The medical records of patients with active UC who were treated with BDP were retrospectively reviewed. Partial Mayo Clinic score (pMS) was calculated to determine disease activity. After 4 weeks of therapy, clinical remission, clinical response, and response failure rates were evaluated. Clinical remission was defined as a post-treatment pMS of 0 or 1, clinical response as a decrease of two of three points in pMS and >30% from baseline, and response failure as a lack of clinical response. Also, we considered that clinical remission was included in clinical response. RESULTS: Between July 2013 and April 2015, 95 patients with UC received BDP therapy at our institution (median age, 44 years; range, 12-81 years). After 4 weeks of therapy, clinical remission and clinical response rates were 50.5% and 73.7%, respectively. Mean change of pMS before and after BDP therapy was 2.4. There was no significant side effect reported. In multivariate analysis, disease activity was the only factor associated with a favorable response. Clinical remission rate was significantly higher in the mild disease activity group (66.7%) than that in the moderate or severe disease activity group (41.9%) (p=0.024). CONCLUSION: BDP is efficacious in inducing a clinical response or remission in Korean patients with UC. Patients with mild UC were more likely to be in remission than those with moderate or severe UC after receiving BDP for 4 weeks. BDP exhibited a good safety profile.
Files in This Item:
T201700030.pdf Download
DOI
10.3349/ymj.2017.58.1.144.
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Won Ho(김원호) ORCID logo https://orcid.org/0000-0002-5682-9972
Kim, Tae Il(김태일) ORCID logo https://orcid.org/0000-0003-4807-890X
Park, Soo Jung(박수정)
Yoo, SunHo(유선호)
Lee, Yoon Jee(이윤지)
Lee, Hyun Jung(이현정)
Cheon, Jae Hee(천재희) ORCID logo https://orcid.org/0000-0002-2282-8904
Hong, Sung Pil(홍성필)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/154166
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse